Proximo Medical has announced that it has been selected as the marketing and commercial partner for Walk Vascular, a medical device company that has developed JETi, a novel peripheral thrombectomy catheter.
Proximo Medical is a fractional commercial organisation for start-up medical device technologies that delivers market validation, an experienced workforce and scalability to deliver accelerated revenues, a press release states.
Walk Vascular has just released its new JETi 88 device, which employs an internal jet, located inside its catheter mouth, capable of engaging large thrombus volumes through a miniature lumen, rapidly clearing peripheral vessels that would prove difficult and frequently clog standard aspiration devices.
Last autumn, Jean Cournoyer-Rodrigue (Centre Hospitalier de l’Université de Montréal Research Center in Montreal, Quebec, Canada) presented data from a study assessing the safety and efficacy of the JETi thrombectomy system at CIRSE 2018, the Cardiovascular and Interventional Radiology Society of Europe annual meeting (22–25 September, Lisbon, Portugal).
The system was tested in 23 venous thromboembolism cases with an 83% rate of technical success, defined as restoration of antegrade flow with the elimination of any obstructing lesion without overnight post-procedural lytic infusion via catheter-directed thrombolysis.
“This percentage of ‘single session’ efficacy, with a mean total procedure time of 73 minutes, is quite remarkable relative to the existing literature. Using devices that require adjunctive procedures, intensive care unit stays, is not a win for anyone in the healthcare value chain, especially the patient. Single session devices offer great promise of a new treatment paradigm,” states Cournoyer-Rodrigue.
“By partnering with Proximo Medical we can hit the ground sprinting, with high quality direct sales representatives that start-ups generally cannot afford without the need for additional funding,” comments David Look, president and CEO of Walk Vascular. “Proximo provides a crucial next step absent of most technology developers. Their ability to quickly de-risk commercial viability, confirm reordering patterns and document the salesforce’s ramp time provides huge value to both the developer and potential future acquirer.”
“We are pleased to be working with Walk Vascular and the JETi technology, a proven solution that safely and effectively restores blood flow in coronary and peripheral interventional procedures,” says Brett Martin, Proximo Medical CEO. “With more than 75% of medical device start-ups failing prior to commercialisation, we are proud to partner with innovators like Walk Vascular to provide insights, marketing strategy, and a top-tier salesforce to ensure commercial success and clinical adoption.”
